DermatologyNews.net

Dermatology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Taltz"

The New England Journal of Medicine ( NEJM ) has published detailed results from three pivotal phase 3 studies, UNCOVER-1, UNCOVER-2 and UNCOVER-3, that have demonstrated the efficacy and safety of Ix ...


Ixekizumab ( Taltz ) met the primary and all major secondary endpoints up to week 12 in the phase 4 IXORA-R study, which evaluated the efficacy and safety of Ixekizumab versus Guselkumab ( Tremfya ) i ...